CDXS vs WVE
CDXS: Codexis leverages its proprietary directed evolution technology to engineer high-performance enzymes that optimize the manufacturing of small molecule and RNAi-based therapeutics. WVE: A clinical-stage biotechnology company developing a versatile, multimodal RNA medicine platform to treat rare and common diseases without the need for complex delivery vehicles like lipid nanoparticles.
Side-by-side fundamentals
| Metric | CDXS | WVE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.06 | $5.74 | |
| Market cap as of 2026-07-23 | $200M | $1.1B | |
| PEG as of 2026-07-23 | n/a | -0.11 | |
| Net margin as of 2026-07-23 | -41.0% | -255.7% | CDXS higher |
| Gross margin as of 2026-07-23 | +88.9% | n/a | |
| Operating margin as of 2026-07-23 | -37.5% | -274.2% | CDXS higher |
| ROE as of 2026-07-23 | -68.1% | -55.7% | WVE higher |
| ROA as of 2026-07-23 | -23.7% | -42.8% | CDXS higher |
| Debt / equity as of 2026-07-23 | 0.94 | 0.00 | WVE lower |
| Revenue growth (YoY) as of 2026-07-23 | +56.8% | -31.6% | CDXS higher |
| Revenue CAGR (3y) SEC XBRL | -20.2% | +127.1% | WVE higher |
| Beta as of 2026-07-23 | 2.47 | -1.33 | |
| 1-year return as of 2026-07-22 close | -22.5% | -27.6% | CDXS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.